Finch Therapeutics Group, Inc. (FNCH) stock rallied over 6.64% intraday to trade at $2.41 a share on NASDAQ. The stock opened with a gain of 5.70% at $2.38 and touched an intraday high of $2.55, rising 6.64% against the last close of $2.26. The stock went to a low of $2.23 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue15.33 Million
5Y Sales Change-
Fiscal Year Ends2021-12-30
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
Finch Therapeutics Group, Inc. (NASDAQ: FNCH) stock price is $2.41 as of the last check on Monday, August 8. During the trading session, FNCH stock reached the peak price of $2.55 while $2.23 was the lowest point it dropped to.
The NASDAQ listed FNCH is part of Biotechnology industry that operates in the broader Health Care sector. Finch Therapeutics Group, Inc. , a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States.
Dr. Mark Burnham Smith Ph.D.
CEO & Director
Mr. Marc B. Blaustein C.F.A., CFA, MPP
Chief Operating Officer
Mr. Joseph D. Vittiglio Esq., J.D.
Chief Bus. & Legal Officer and Corp. Sec.
Mr. Gregory D. Perry
Chief Financial Officer
FNCH stock traded closed the last session at $2.41, which is $0.15000000000000036 or 6.637168141592936% lower than its previous close of $2.26. FNCH's current trading price is 40.8% lower than its 52-week high of $17.39 where as its distance from 52-week low of 1.71% is -86.14%.
Number of FNCH employees currently stands at -. FNCH operates from 200 Inner Belt Road, Suite 400, Somerville, MA 02143, United States.
Official Webiste of $FNCH is: https://www.finchtherapeutics.com
FNCH stock volume for the day was 47,434 shares while in the previous session number of FNCH shares traded was 47,433 . The average number of FNCH shares traded daily for last 3 months was 121.63 Thousands.
The percentage change in FNCH stock occurred in the recent session was 6.637168141592936% while the dollar amount for the price change in FNCH stock was $0.15000000000000036.
In the recent session, the day high for FNCH stock was $2.55 while the low for FNCH stock touched on the day was $2.23.
The market value of FNCH currently stands at 112.62 Million with its latest stock price at $2.41 and 47.53 Million of its shares outstanding.